1258597-47-5 Usage
Description
ApreMilast-d5, also known as isotope-labelled Apremilast, is an oral phosphodiesterase 4 (PDE4) inhibitor derived from Apremilast. It is utilized in the medical field for its anti-inflammatory and immunomodulatory properties, making it a promising candidate for various therapeutic applications.
Uses
Used in Pharmaceutical Industry:
ApreMilast-d5 is used as a therapeutic agent for the treatment of psoriatic arthritis. It exerts its effects by inhibiting the activity of PDE4, which in turn leads to an increase in the levels of cyclic AMP (cAMP). This results in the suppression of inflammatory mediators and modulation of the immune response, providing relief from the symptoms of psoriatic arthritis.
Additionally, ApreMilast-d5 may have potential applications in other inflammatory and immunological disorders due to its anti-inflammatory and immunomodulatory properties. However, further research and clinical trials are necessary to establish its efficacy and safety in these contexts.
Check Digit Verification of cas no
The CAS Registry Mumber 1258597-47-5 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,5,8,5,9 and 7 respectively; the second part has 2 digits, 4 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 1258597-47:
(9*1)+(8*2)+(7*5)+(6*8)+(5*5)+(4*9)+(3*7)+(2*4)+(1*7)=205
205 % 10 = 5
So 1258597-47-5 is a valid CAS Registry Number.
1258597-47-5Relevant articles and documents
SUBSTITUTED ISOINDOLINE-1,3-DIONE DERIVATIVES
-
, (2018/11/02)
PURPOSE: A novel substituted isoindoline-1,3-dione derivative is provided to improve drug compliance and to treat diseases caused by PDE4 or TNF-alpha. CONSTITUTION: A novel substituted isoindoline-1,3-dione derivative is denoted by chemical formula I. Th
SUBSTITUTED ISOINDOLINE-1,3-DIONE DERIVATIVES
-
Page/Page column 17-18, (2010/12/31)
This invention relates to novel substituted isoindoline-1,3-dione derivatives and pharmaceutically acceptable salts thereof. More specifically, the invention relates to novel substituted isoindoline-1,3-dione derivatives that are analogues of apremilast.
